Tri Locum Partners LP Femasys Inc Transaction History

Tri Locum Partners LP

$278 Million
Q2 2025

A detailed history of Tri Locum Partners LP transactions in Femasys Inc stock. As of the latest transaction made, Tri Locum Partners LP holds 30,606 shares of FEMY stock, worth $19,587. This represents 0.01% of its overall portfolio holdings.

Number of Shares

30,606

Previous 30,606 -0.0%

Holding current value

$19,587

Previous $38,000 23.68%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.75 - $2.22 $4,158 - $12,307	-5,544 Reduced 15.34%	30,606 $47,000
Q4 2023 Feb 14, 2024	SELL	$0.76 - $3.89 $30,745 - $157,369	-40,455 Reduced 52.81%	36,150 $35,000
Q3 2023 Nov 14, 2023	SELL	$0.31 - $2.98 $10,881 - $104,600	-35,101 Reduced 31.42%	76,605 $228,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $1.26 $7,535 - $18,617	-14,776 Reduced 11.68%	111,706 $56,000
Q1 2023 May 15, 2023	BUY	$0.85 - $1.29 $20,174 - $30,618	23,735 Added 23.1%	126,482 $136,000
Q4 2022 Feb 14, 2023	SELL	$0.83 - $1.41 $3,202 - $5,441	-3,859 Reduced 3.62%	102,747 $92,000
Q3 2022 Nov 14, 2022	BUY	$1.13 - $2.54 $25,735 - $57,848	22,775 Added 27.17%	106,606 $120,000
Q2 2022 Aug 15, 2022	SELL	$1.3 - $2.76 $5,357 - $11,373	-4,121 Reduced 4.69%	83,831 $202,000
Q1 2022 May 16, 2022	SELL	$1.76 - $3.99 $101,515 - $230,139	-57,679 Reduced 39.61%	87,952 $199,000
Q4 2021 Feb 14, 2022	SELL	$3.49 - $8.02 $156,941 - $360,651	-44,969 Reduced 23.59%	145,631 $568,000
Q3 2021 Nov 15, 2021	BUY	$6.52 - $8.5 $12,042 - $15,699	1,847 Added 0.98%	190,600 $1.31 Million
Q2 2021 Aug 16, 2021	BUY	$7.98 - $12.0 $1.51 Million - $2.27 Million	188,753 New	188,753 $1.53 Million

Others Institutions Holding FEMY

# of Institutions

Shares Held

5.08M

Call Options Held

Put Options Held

View Full List

About FEMASYS INC

Ticker FEMY
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 11,813,600
Market Cap $7.56M
Description
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support...

More about FEMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.

Account

Tri Locum Partners LP Femasys Inc Transaction History